Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 808

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 808
---
 USD $118 and $129 thousand, net. NOTE 10: — TRADE PAYABLES

|                                                                   |     |      December 31 |     |      |
|                                                                   |     |             2024 |     | 2023 |
|                                                                   |     | USD in thousands |     |      |
| Open accounts                                                     |     |              206 |     |  133 |
| Accrued expenses                                                  |     |              146 |     |  399 |
| Merger Expenses Payable in Connection with the Merger Transaction 
 with NLS                                                          |     |              216 |     |    — |
|                                                                   |     |              568 |     |  532 |

Note 11: — Accounts payable

|                                 |     |      December 31 |     |      |
|                                 |     |             2024 |     | 2023 |
|                                 |     | USD in thousands |     |      |
| Deferred Grants see Note 17F    |     |               42 |     |    — |
| NLS Current account**           |     |              400 |     |    — |
| Employees and payroll accruals* |     |              163 |     |  226 |
|                                 |     |              605 |     |  226 |

____________ * Includes a bonus in the amount of USD $82 thousand in respect of a liability to related parties (see Note 22). ** A total of NIS 1,496 thousand (USD $400 thousand) was received on November 20, 2024 from the Swiss biopharmaceutical company NLS Pharmaceutics Ltd (“NLS”). This amount represents a current account between the Company and NLS intended for the settlement of future shared costs related to the merger transaction. The unused balance of the current account will be settled upon completion of the merger.

Annex G-19

KADIMASTEM LTD.
NOTES TO FINANCIAL STATEMENTS Note 12: — CONTINGENT liabilities to the Innovation Authority in respect of royalties A.The Company received grants from the government of Israel for participation in research and development, and in exchange, it committed to pay royalties at a rate of 3% from sales of the research and development outcomes that were funded up to the total grants received, dollar -linkedand plus interest at the LIBOR interest (see Note 2C). B.On March 2, 2022, the Company received the approval of the IIA to